ENLIVEN THERAPEUTICS INC

ELVNNASDAQ

🏆 #1374 by market capEarnings Nov 11US Equity

$59.02▲ $0.24 (+0.41%)

Live

1h▲ 0.1%

24h▲ 0.4%

7d▼ 1.2%

14d▲ 11.6%

30d▲ 16.0%

1y▲ 212.3%

🏦Market Cap

$4.12B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $58.67 – $59.54
52-Week Range: $14.79 – $62.32
Volume: $1.72B
Avg Volume: $2.12B
Shares Outstanding: 69.8M
Next Earnings: Oct 14, 2026

Fundamentals Snapshot

Annual Revenue: $644M
Last Q Revenue: $151M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.67
Dividend Yield: —

Why Investors Own ELVN

✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$644M▲ +39.5% YoY

Gross Margin (TTM)

48.9%▲ +0.8% YoY

Operating Income (TTM)

$196M▲ +39.5% YoY

Free Cash Flow (TTM)

$185M▲ +39.5% YoY

About ENLIVEN THERAPEUTICS INC

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

🦦